Biblio

Author Title [ Type

] Year

Filters: Author is Wendtner, Clemens-Martin [Clear All Filters]

Journal Article

Cramer P, von Tresckow J, Fink A-M, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, et al. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Am J Hematol. 2024.

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(19):1739-1754.

Ecker V, Brandmeier L, Stumpf M, Giansanti P, Moreira AVarela, Pfeuffer L, Fens MHAM, Lu J, Kuster B, Engleitner T, et al. Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. Cell Rep. 2023;42(10):113017.

Eichenauer DA, Bühnen I, Plütschow A, Kobe C, Dietlein M, Wendtner C-M, Thorspecken S, Topp MS, Mauser M, von Tresckow B, et al. Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Hematol Oncol. 2022.

von Tresckow J, Cramer P, Robrecht S, Langerbeins P, Fink A-M, Al-Sawaf O, Fürstenau M, Illmer T, Klaproth H, Tausch E, et al. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia. 2022.